Picture of Jubilant Pharmova logo

JUBLPHARMA — Jubilant Pharmova News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Jubilant Pharmova Completes Safety Studies For Novel Oral Formulation Of Remdesivir

April 19 (Reuters) - Jubilant Pharmova Ltd  JUBA.NS :
    * COMPLETES SAFETY STUDIES IN ANIMALS, HEALTHY HUMANS IN
INDIA
USING NOVEL ORAL FORMULATION OF REMDESIVIR
    * HAS SOUGHT AUTHORIZATION FOR ADDITIONAL STUDIES FOR NOVEL
ORAL
REMDESIVIR FORMULATION FROM INDIA REGULATORS
    * PROPOSED ORAL REMDESIVIR TREATMENT FOR COVID-19 EXPECTED
TO BE
FOR 5 DAYS

Source text for Eikon:  ID:nBSEbvSC3k 
Further company coverage:  JUBA.NS 

 ((bangalore.newsroom@thomsonreuters.com;))

Recent news on Jubilant Pharmova

See all news